Salisbury, United Kingdom

Alan Doyle


Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 1996-1997

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Alan Doyle: Innovator in Monoclonal Antibodies

Introduction

Alan Doyle is a prominent inventor based in Salisbury, GB, known for his significant contributions to the field of immunology. He holds a total of 4 patents, focusing primarily on human monoclonal antibodies that play a crucial role in blood typing and preventing hemolytic disease of the newborn.

Latest Patents

Doyle's latest patents include innovative human anti-Rh(D) monoclonal antibodies. The first patent describes antibodies that bind specifically to the Rh(D) antigen while avoiding other antigens in the Rh blood group system. These antibodies are characterized as IgG1 proteins with kappa light chains and are designed for Rh-typing of red blood cells. The second patent outlines similar antibodies, but these are classified as IgG3 proteins and are of the allotype G3m(21). Both patents exemplify the monoclonal antibodies from specific cell lines deposited at the European Collection of Animal Cell Cultures in 1987.

Career Highlights

Alan Doyle is currently associated with the National Blood Authority, where he continues to advance research in blood-related immunology. His work has been instrumental in developing methods that enhance the safety and efficacy of blood transfusions.

Collaborations

Doyle has collaborated with notable colleagues, including Belinda Mary Kumpel and Benjamin Arthur De Burgh Bradley, contributing to the advancement of research in his field.

Conclusion

Alan Doyle's innovative work in monoclonal antibodies has made a significant impact on immunology and blood safety. His patents reflect a commitment to improving healthcare outcomes through scientific research and collaboration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…